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Purpose: We evaluated the contributions of coagulation factors IIa (thrombin) and Xa to  
small-diameter p osthetic graft thrombogenicity n vivo. 
Methods: Preclotted and nonpreclotted (collagen-coated) polyester grafts were studied 
before and 24 hours after implantation i to pig femoral arteries. After incubation of 
explanted grafts was performed with plasma depleted of vitamin K-dependent coagula- 
tion factors by barium chloride adsorbtion (Ba-plasma), graft-associated thrombin activ- 
ity was determined by radioimmunoassay for fibrinopeptide A. Fibrinopeptide A levels 
reflect thrombin-mediated fibrin formation. Factor Xa activity was characterized by 
measuring activation of prothrombin added to Ba-plasma. 
Results: Thrombin and factor Xa were associated with the luminal surfaces of preclotted 
grafts before and 24 hours after implantation. Nonpreclotted grafts had negligible 
procoagulant activity before implantation. After 24 hours in vivo graft-associated factor 
Xa activity was similar in both nonpreclotted and preclotted grafts; however, more 
thrombin was bound to nonpreclotted coated grafts (p < 0.01). 
Conclusions: The procoagulant activity of small-diameter p osthetic grafts persists for 24 
hours after implantation and is attributable not only to graft-associated thrombin but 
also to de novo thrombin elaboration i duced by factor Xa. Moreover, graft-associated 
procoagulant activity is not dependent on preclotting because it develops on nonpreclot- 
ted, collagen-coated grafts as well. Treatment strategies to attenuate graft thrombosis 
may require the inhibition of both thrombin and factor Xa. (J Vasc Surg 1997; 
25:730-5.) 
The widespread use of small-diameter p osthetic 
grafts for distal lower extremity revascularization has 
been limited by their high early failure rates. ~ Al- 
though the graft material itself is inert, 2 the rapid 
accumulation of coagulation proteins on the lumi- 
nal surface after implantation results in significant 
graft-associated procoagulant activity. 3,4 This has 
prompted the search for new strategies to reduce 
graft thrombogenicity. The development of  novel 
therapeutic approaches i dependent on a detailed 
knowledge of coagulation protein deposition on 
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prosthetic grafts. It is surprising that little informa- 
tion is available about the relative contributions of 
individual coagulation factors to graft procoagulant 
activity. 
Blood coagulation is ultimately dependent on the 
activation of  factor II (prothrombin) to factor IIa 
(thrombin), which cleaves soluble fibrinogen into 
insoluble fibrin, activates platelets, and potentiates 
procoagulant activity by activating factors V and 
VIII. Both thrombin and factor Xa/Va, the complex 
that activates prothrombin, bind to platelet-rich 
thrombi and may play a role in graft thrombogenic- 
ity. Our laboratory has previously shown that the 
procoagulant activity of whole blood clots is not 
solely due to thrombin but also to clot-bound factor 
Xa/Vafi Determining the relative contribution of 
each coagulation factor to graft thrombogenicity is 
important, because an anticoagulant active against 
one coagulation factor does not necessarily inactivate 
others. This study was designed to determine the 
specific contributions of  coagulation factor Xa and 
thrombin to prosthetic graft thrombogenicity n vivo 
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with small-diameter g afts implanted in the arterial 
circulation of pigs. 
MATERIAL  AND METHODS 
Animal studies. Domestic pigs weighing 25 to 
35 kg were anesthetized with an intramuscular com- 
bination ofketamine, xylazine, tiletamine, and zolaz- 
epam (5 mg/kg of each), intubated, and ventilated 
with oxygen-enriched room air for the duration of 
the surgery on a respirator. Blood gas analysis was 
used to adjust ventilation. Sedation was maintained 
with intermittent intravenous dosing of pentobarbi- 
tal. Twenty milliliters of blood was drawn percutane- 
ously and used for graft preclotting. 
The femoral bifurcations were isolated bilaterally 
with vertical groin incisions. The superficial femoral 
artery was replaced with a 4 cm long, 4 mm diameter 
segment of prosthetic graft implanted in an end-to- 
end fashion with running 6-0 polypropylene suture 
at both ends. No systemic anticoagulation was used. 
At the end of surgery the wounds were closed in 
layers, and the animals were allowed to recover. After 
24 hours the animals were reanesthetized, and a 
midline abdominal incision was used to isolate the 
distal abdominal aorta. A cannula was placed in the 
distal aorta to irrigate both femoral grafts with 250 
ml of phosphate-buffered saline solution at physio- 
logic pressure. The grafts were then harvested with 
the adjacent 1 cm of native vessel at both the proxi- 
mal and distal anastomoses. Each harvested unit was 
then divided into three 2 cm long segments o reflect 
the proximal anastomotic area, the midgraft, and the 
distal anastomotic area. 
Grafts used in this study included knitted polyes- 
ter grafts (Dacron, a gift of Meadox Medical, Oak- 
land, N.J.) and collagen-coated knitted polyester 
grafts (Hemashield, a gift of Meadox Medical). Col- 
lagen-coated grafts are impervious to blood at arte- 
rial pressure and did not require preclotting be- 
fore implantation. The noncoated polyester grafts 
were preclotted for 10 minutes with whole blood 
and were then mechanically stripped of gross clot 
before implantation. Prcclotting of noncoated grafts 
is required to render the graft impervious to blood 
under arterial pressure and is standard clinical proce- 
dure. 
We tested preclotted noncoated grafts that were 
not exposed to circulating blood and preclotted non- 
coated grafts that had been implanted into the fem- 
oral arterial circulation for 24 hours. Similarly, we 
tested collagen-coated grafts never exposed to blood, 
exposed to blood ex vivo for 1 minute, or implanted 
in vivo for 24 hours. Pigs were randomized to receive 
either two preclotted grafts, two collagen-coated 
grafts, or one of each. This procedure was done to 
minimize the effect of interanimal variabili~. 
Preparation of  reagents. Graft-associated 
thrombin activity was characterized by measuring 
fibrin formation induced by grafts incubated with 
recalcified plasma depleted of vitamin K-depen- 
dent coagulation factors (factors II, VII, IX, and 
X) by barium adsorbtion. Fibrin formation was 
characterized by measuring thrombin activity in- 
duced by activation of 0.9 Ixm prothrombin added 
to recalcified barium-adsorbed plasma incubated 
with grafts. 
Adsorbtion of  plasma by barium chloride (Ba- 
plasma). In brief, pooled frozen citrated human 
plasma was purchased from the American Red Cross 
(St. Louis, Mo.) and stir-mixed in a 9:1 ratio with 1 
mol /L  barium chloride in an ice bath fbr 30 minutes. 
The mixture was then centrifuged at 3000 rpm for 
15 minutes, the supernatant collected, and the pro- 
cedure repeated. The supernatant was then dialyzed 
in 25 mmol /L  sodium citrate buffer containing 150 
mmol /L  chloride at pH 7.0 overnight to remove the 
barium chloride. At the completion of dialysis any 
remaining precipitate was centrifuged, and the 
plasma was stored at -70  ° C until use .  6 
Preparation of  prothrombin. Human pro- 
thrombin was purchased from Hematologic Tech- 
nologies Inc. (Essex Junction, Vt.) and treated with 
5 mmol/L  D-Phe-L-Pro-L-Arg-chloromethylketone 
(PPACK, a thrombin inhibitor) to remove any contam- 
inating thrombin. The mixture was then dialyzed three 
times, 6 hours each time, against a200 mmol/L N-2- 
hydroxyethylpiperazine-N-2-ethanesulfonic acid buffer 
containing 150 mmol/L sodium chloride to remove 
the PPACK before use. The lack of contaminating 
active thrombin was verified by the absence of FPA 
generation when the prothrombin was incubated with 
recalcified Ba-plasma. 
Measurement of  thrombin and factor Xa 
activities 
Measurement of thrombin activity. Each 2 cm 
graft segment was closed at one end with a silk tie to 
allow the lumen to be filled with the testing solu- 
tions. Each segment was then filled with 150 ~1 of 
recalcified (25 mmol /L  CaCI 2) Ba-plasma nd incu- 
bated at 37 ° C for 15 minutes. The plasma was then 
removed, treated with 17 bd of an anticoagulant 
mixture (consisting of PPACK and aprotinin to in- 
hibit thrombin and ethylenediaminotetraacetic acid), 
and immediately placed on ice to stop all coagulation 
reactions. The mixture was then stirred in a benton- 
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Fig. 1. Standard curves demonstrating amount of FPA generated by increasing concentrations 
of thrombin (left) or factor Xa (right). Relationship between thrombin and FPA generation is 
linear, described by equation y = 798.946x + 131.888. Exponential equation y -- (18.769) 
(10 °'sl9x) describes relationship between factor Xa concentration a d FPA generation. 
Table I. Increase in FPA (in ng/ml)  
attributable to thrombin and factor Xa on 
preclotted grafts 
0 hours 24 hours p value 
Thrombin 2448 + 347 2134 + 154 0.34 
Factor Xa 4017 + 1555 4815 +- 416 0.48 
Results are reported as mean -+ SEM. 
ite slurry in a 1:2 volume ratio to precipitate any 
unused fibrinogen and was centrifuged at 2000g for 
20 minutes. The supernatant was then collected, and 
its level of  FPA was measured with a commercially 
available radioimmunoassay kit (Byk-Sangtec Diag- 
nostica, Dietzenbach, Germany). The lower detec- 
tion limit of this assay is 0.1 ng/ml.  Because the 
Ba-plasma contains no thrombin, the FPA level mea- 
sured directly reflects luminal graft-associated 
thrombin activity. This activity was quantified by 
comparison to standard curves. 
Measurement o f  factor Xa activity. After assays 
were obtained for thrombin activity, the graft seg- 
ments were washed thoroughly three times with 
large volumes of phosphate-buffered saline solution 
at 37 ° C. Each segment was then filled with 150 ~1 
of recalcified (25 mmol /L  CaC12) Ba-plasma, to 
which 0.9 mmol /L  of purified thrombin-free pro- 
thrombin had been added. After a 15-minute incu- 
bation at 37 ° C plasma was removed and processed 
as described previously. Graft-associated factor Xa 
cleaved the added prothrombin i to thrombin, which 
induced additional elaboration of FPA compared with 
that generated by graft-associated thrombin alone. The 
FPA levels measured by radioimmunoassay under these 
conditions reflected the graft-associated activities of 
both factor Xa and thrombin. By subtracting from the 
FPA generated by both factor Xa and thrombin activi- 
ties that were due to thrombin alone, the FPA value 
attributable to factor Xa alone was calculated. Graft- 
associated factor Xa was quantified by comparison to 
standard curves. 
Statistical analysis. Comparisons were per- 
formed with unpaired two-tailed Student tests un- 
less otherwise specified. The significance l vel was set 
at p < 0.05. 
RESULTS 
Six separate preclotted polyester grafts were stud- 
ied before implantation. A total of  seven preclotted 
polyester grafts were implanted into the femoral ar- 
terial circulation for 24 hours; thus 21 segments wer e 
studied. After preclotting alone FPA generation was 
measured, reflecting thrombin (2448 + 347 ng/ml  
FPA) and factor Xa (4017 + 1555 ng/ml  FPA). 
After 24 hours of implantation in vivo significant 
FPA reflecting activities of both thrombin (2134 + 
154 ng/ml  FPA) and factor Xa (4815 + 416 ng/ml  
FPA) were tightly associated with all preclotted poly- 
ester grafts (Table I). FPA induced by thrombin and 
factor Xa after preclotting alone was not statistically 
different from values measured after 24 hours of 
implantation i  vivo. Based on comparison with pu- 
rified proteins added to the same plasma, bound 
thrombin and factor Xa concentrations after 24 
hours of implantation were estimated to be 2.8 nm 
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Table II. Comparison of FPA (in ng/ml)  generated by thrombin and factor Xa in different graft 
regions at 24 hours 
Proximal graft Mid graft Distal graft p value (ANO VA) 
Thrombin  2144 _+ 221 2123 _+ 327 2166 _+ 236 0 .99 
Factor  Xa 4239 _+ 799 4985 _+ 795 5219 -+ 615 0 .63 
Results are repor ted  as mean + SEM,  with n = 7 ~br all values. 
and 4.6 nm, respectively (Fig. 1). This is equivalent 
to 7 ng of thrombin and 18 ng of factor Xa bound 
per centimeter of graft length. 
There were no differences in FPA generation re- 
flecting thrombin or factor Xa activities between 
proximal anastomotic, mid-graft, or distal anasto- 
motic graft regions with preclotted polyester grafts 
implanted for 24 hours (Table II). 
To determine the contribution of the preclotting 
process to graft-associated procoagulant activity, col- 
lagen-coated grafts were tested. These collagen- 
coated grafts were not preclotted and were studied 
before any blood exposure (n = 6), after blood 
exposure ex vivo for 1 minute (n = 6), or after 
implantation i to the femoral arterial circulation for 
24 hours (n = 12). Grafts not exposed to blood 
exhibited essentially no thrombin or factor Xa activ- 
ity, reflected by FPA values of 83 + 31 ng/ml  and 
318 _+ 252 ng/ml,  respectively (Table III). In con- 
trast, collagen-coated grafts exposed to blood for as 
little as 1 minute exhibited significant graft-associ- 
ated thrombin (1897 _+ 42 ng/ml  FPA) and factor 
Xa (2943 _+ 399 ng/ml  FPA) activity. Moreover, 
although the FPA generated by thrombin (4098 _+ 
554 ng/ml  FPA) and factor Xa (3372 + 748 ng/ml  
FPA) activities at 24 hours were higher than at 1 
minute, the differences were not statistically signifi- 
cant. Significantly more thrombin activity was 
present on the luminal surface of the graft after either 
24 hours of exposure to arterial blood flow in vivo 
(p < 0.0001) or after I minute of exposure to whole 
blood (p < 0.0001) than was present before implan- 
tation. Also, significantly increased factor Xa activity 
was measured after both 1 minute (p = 0.0007) or 
24 hours (p = 0.01) compared with preimplantation 
factor Xa activity. 
At 24 hours after implantation preclotted polyes- 
ter grafts trended towards increased factor Xa activity 
compared with collagen-coated grafts, although the 
difference was not statistically significant (FPA values 
of 4815 -+ 416 and 3372 _+ 748 ng/ml  FPA, respec- 
tively, p -- 0.08). However, graft-associated throm- 
bin activity was significantly lower on preclotted 
polyester grafts compared with collagen-coated poly- 
Table II I .  FPA (in ng/ml) generated by 
thrombin and factor Xa on collagen-coated 
grafts (not preclotted) 
0 hours I minute 24 hours 
Thrombin  83 -+ 31 1897 _+ 42 4098 -+ 554 
Factor  Xa 318 -+ 252 2943 _+ 399 3372 -+ 748 
Results are reported as mean _+ SEM. 
ester grafts (FPA values of 2134 + 154 and 4098 + 
554 ng/ml,  respectively; p < 0.01). Finally, preclot- 
ted polyester grafts immediately before implantation 
were not different from collagen-coated, nonpreclot- 
ted polyester grafts that had been exposed to circu- 
lating blood for only 1 minute (p = 0.31 and 0.65 
for thrombin and factor Xa activities, respectively). 
DISCUSSION 
Efforts at biochemically rendering rafts less than 
thrombogenic have been hampered by a lack of 
knowledge about the relative contributions of the 
coagulation factors to graft thrombogenicity. Most 
prcvious tudies dealing with graft thrombogenicity 
have focused on the role ofplatclets in this process. 7,8 
Two previous reports in the literature have at- 
tempted to assess the contribution of coagulation 
factors to graft thrombogenicity. 9,1° 
In a study of left ventricular assist devices Wagner 
et al. 9 detected minimal thrombin activity both at the 
time of implantation and removal of Dacron graft 
connections. The binding of other coagulation fac- 
tors were not evaluated. The grafts studied were 
large-caliber, unlike the ones used for lower extrem- 
ity revascularization. 
Kelly et al. 1° characterized bound coagulation 
factors in a baboon model of exteriorized high-flow 
Dacron segments in chronic arteriovirus hunts. 
Chromogenic substrates were used to characterize 
thrombin and factor Xa activity. Factor Xa activity, 
although present initially, was not detectable 1 hour 
after graft interposition into the shunt. Bound 
thrombin activity was detected immediately and did 
not decrease significantly over a 24-hour period. 
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In this study we found significant and sustained 
thrombin and factor Xa activities at the time of im- 
plantation and after 24 hours. Our results may differ 
from those of Kelly et al. for several reasons. The 
chromogenic assay used by Kelly et al. to detect 
factor Xa activity may be less sensitive than the assay 
we used, which is based on measuring prothombin 
activation by the factor Xa/Va complex. Because of 
the amplification present at each step in the coagula- 
tion casacade, the technique used in our study en- 
hances detection of factor Xa activity by elaboration 
of thrombin and generation of FPA. Because of this 
amplification small increases in factor Xa activity are 
reflected as large changes in FPA values (Fig. 1). In 
addition, the model we used has been reported to be 
significantly thrombogenic in other animals, a~ a fact 
possibly related to the small size of the grafted fem- 
oral artery or the significant outflow resistance of the 
lower extremity arterial bed. The model used by 
Kelly et al. involved high flow rates in an arterio- 
venous fistula and did not involve the creation of any 
surgical anastomosis at the rime of graft interposi- 
tion. We believe our model has a direct relevance to 
the human clinical situation, in which a distal pros- 
thetic bypass graft is sutured to the donor and recip- 
ient vessels, graft flow rates and velocities are modest, 
and there is significant outflow resistance. 
The deposition of thrombin and factor Xa activi- 
ties on polyester grafts does not appear to be a 
unique consequence of the preclotting process, be- 
cause collagen-coated grafts that were not preclotted 
exhibited similar procoagulant activity after even 
brief exposure to blood. The differences in thrombin 
activity observed at 24 hours between oncoated and 
collagen-coated grafts are of unclear biologic signifi- 
cance. Collagen-coated grafts at 24 hours exhibited 
higher levels of graft-associated thrombin activity 
than noncoated preclotted grafts at the same rime 
point. This result could be related to additional co- 
agulation factor or platelet activation by graft-bound 
collagen. However, the clinical importance of a mod- 
est increase in thrombin activity on collagen-coated 
grafts is uncertain, because these grafts are currently 
used only in large-diameter, high-flow arterial recon- 
structions. The observation that the proximal and 
distal segments contain only half the prosthetic graft 
length of the middle segment but generate quiva- 
lent amounts of FPA may be attributable to native 
vessel trauma nd induction ofprocoagulant activity 
on the native vessel segment with anastomosis. Al- 
though direct comparisons are difficult because of 
differences in the models used, the amounts of 
thrombin and factor Xa activities een in other stud- 
ies 12'1s after vessel injury alone appear to be lower 
than those noted in this study. 
Further studies are still required to determine 
thrombin and factor Xa activity after long-term graft 
implantation. A recent experimental study of Dacron 
grafts in the thoracic aorta of dogs suggested that 
gross thrombus formation on the luminal surface can 
continue to take place for years after implantation. ~4
Given our data it is no surprise that heparin does 
not passivate small-diameter prosthetic grafts, in view 
of its lack of effectiveness against clot-bound throm- 
bin. is A variety of single agents have been studied in 
the experimental setting to decrease graft thrombo- 
genicity, but none has achieved widespread clinical 
use. Our results suggest that a combination of anti- 
coagulants targeting both factor Xa and thrombin 
perhaps in combination with antiplatelet agents 
might be required to effectively decrease the pro- 
thrombotic tendencies of small-diameter p osthetic 
grafts. The prothrombinase complex requires aphos- 
pholipid or platelet membrane to be active; thus 
inhibiting platelets may have the added benefit of 
further reducing thrombin and factor Xa activities. 
We have previously reported on the use of recombi- 
nant tissue factor pathway inhibitor, a natural inhib- 
itor of tissue factor-VIIa and factor Xa, to decrease 
graft thrombogenicity in this model? 6Although ef- 
fective, recombinant tissue factor pathway inhibitor 
alone was not sufficient to achieve full passivation of 
grafts. A "cocktail" ofinhibitors, for example hirudin 
(a thrombin inhibitor) plus tick anticoagulant pep- 
tide (a factor Xa inhibitor) plus a potent platelet 
inhibitor may be required to minimize graft throm- 
bogenicity, although titrating combinations of drugs 
to achieve the desired therapeutic result while avoid- 
ing hemorrhage may prove challenging. Antithrom- 
boric agents might also have a beneficial effect on the 
development of neointimal hyperplasia by inhibiting 
thrombin and factor Xa, both of which have been 
shown to be significant smooth muscle cell mito- 
gens? 7,1s Indeed, when used after balloon angio- 
plasty of atherosclerotic vessels, both thrombin and 
factor Xa inhibitors have been shown to reduce the 
restenosis rate. 19,2° 
In summary, we have shown that thrombin and 
factor Xa are rapidly deposited on prosthetic grafts in 
biologically and clinically significant amounts and have 
demonstrated that procoagulant activity attributable to
these factors is sustained for at least 24 hours. 
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